CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it ...
Development of an In Vivo Non-Viral Ocular Editing Platform and Application to Potential Treatments for Glaucom ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics ...
Strategic Priorities and Recent Advancements 2025 is an important inflection year for CRISPR Therapeutics as we establish ... CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy ...
Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback